Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation reports news about its global life sciences business, which supplies reagents, analytical instruments and precision diagnostics for research, biopharmaceutical, biotechnology and clinical diagnostic customers. Company updates commonly cover financial results, cash dividends, investor conference presentations and demand trends across large pharma, emerging biotech and academic markets.
Product news centers on Bio-Techne's R&D Systems™, Bio-Techne Spatial™ and Bio-Techne Diagnostics™ portfolios. Recent recurring themes include spatial biology workflow additions for the COMET™ suite, SPYRE™ antibody panels and amplification kits, GMP-grade reagents for cell and gene therapy workflows, and the Ella cartridge-based immunoassay platform for translational research and clinical applications.
Bio-Techne (NASDAQ: TECH) reported second quarter fiscal 2026 revenue of $295.9 million, essentially flat year-over-year, with GAAP EPS of $0.24 and adjusted EPS of $0.46. Adjusted operating margin was 31.1%, up 100 basis points versus prior year, while GAAP operating income rose 15% to $54.5 million.
Management cited productivity initiatives and the Exosome Diagnostics divestiture as drivers of margin improvement, with continued strength in large pharma and growth in China/APAC. A conference call and replay are available February 4, 2026.
Bio-Techne (NASDAQ: TECH) launched Cultrex Synthetic Hydrogel on February 2, 2026, a fully defined synthetic extracellular matrix (ECM) for 3D stem cell and organoid culture. The product aims to reduce lot-to-lot variability, support scalable workflows, and align organoid research with regulatory and translational initiatives.
The hydrogel is presented as a synthetic alternative to animal-component matrices to improve reproducibility, traceability, and adoption of new approach methodologies (NAMs) in drug screening, toxicology, and personalized medicine.
Bio-Techne (NASDAQ: TECH) launched Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform on January 28, 2026, enabling femtogram-level detection of neurological biomarkers including NFL, GFAP, pTau 217, and Amyloid β (aa1-42).
The assays deliver improved analytical sensitivity, automated microfluidic workflow with under three-hour runtime, and build on Ella's extensive publication record to support earlier detection and reproducible quantification in neuroscience research. Assays are for Research Use Only.
Bio-Techne (NASDAQ: TECH) will host a conference call and webcast on Wednesday, February 4, 2026 at 8:00 a.m. CST to review second quarter fiscal 2026 financial results.
Live access: dial 1-800-579-2543 or 1-785-424-1789 (international) using Conference ID TECHQ2, or join the webcast at https://investors.bio-techne.com/ir-calendar. A recorded rebroadcast will be available from 11:00 a.m. CST on Feb 4, 2026 through 11:00 p.m. CST on Mar 4, 2026 by dialing 1-844-512-2921 or 1-412-317-6671 and referencing Conference ID 11160826.
Bio-Techne (NASDAQ: TECH) announced that Kim Kelderman, President and CEO, will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:00 a.m. PST. A live webcast will be available via the company's Investor Relations Calendar page.
Investors can access the presentation through the IR Calendar on Bio-Techne's investor relations website.
Bio-Techne (NASDAQ: TECH) announced a strategic collaboration with the Wyss Center Geneva on Dec 11, 2025 to develop an automated workflow for simultaneous RNA and protein detection in 3D tissue specimens. The project aims to extend Bio-Techne's multiomic spatial biology capabilities from 2D into intact 3D samples, enabling high-resolution multiomic analysis in thicker sections.
The collaboration targets automation to reduce manual complexity, accelerate drug discovery and diagnostic development, and support New Approach Methodologies (NAMs) such as organoids and AI-driven predictive modeling to potentially reduce animal testing. Executives from both organizations cited the partnership as a step to broaden accessibility of spatial biology tools for preclinical research.
Bio-Techne (NASDAQ: TECH) launched and shipped its enhanced Leo System on Dec 9, 2025, an upgraded Simple Western platform combining chemiluminescence with dual-channel near-infrared and infrared fluorescence for expanded multiplexing.
Key capabilities include up to 24 targets per sample, support for multiplexing same-weight targets and proteoform pairs (e.g., phosphorylated vs total), resampling and RePlex workflows, processing up to 100 capillaries in three hours, and reported precision of 5–6% variability. The system also includes features to support 21 CFR Part 11 compliance.
Bio-Techne (NASDAQ: TECH) will present at three investor conferences in early December 2025.
Events and times:
- Evercore Healthcare Conference — December 2, 2025 at 8:20 AM ET
- Citi Global Healthcare Conference — December 3, 2025 at 3:15 PM ET
- Nasdaq Investor Conference — December 9, 2025 at 9:30 AM GMT
A live webcast of each presentation will be available via Bio-Techne's investor relations IR Calendar page: https://investors.bio-techne.com/ir-calendar.
Bio-Techne (NASDAQ: TECH) announced on November 18, 2025 a licensing agreement with Monod Bio granting Bio-Techne exclusive commercial rights to a subset of Monod's NovoBody™ Duo molecules, a class of AI-designed bispecific binding proteins.
The deal expands Bio-Techne's recombinant protein and diagnostics portfolio with compact, tunable, multi-specific designs aimed at research and next-generation diagnostics, and is presented as aligning with the company's strategic growth pillars in AI-enabled precision medicine.
Bio-Techne (NASDAQ: TECH) will present at four investor conferences in November 2025. Scheduled presentations:
- UBS Global Healthcare — November 10, 2025 at 10:15 AM ET
- Stifel Healthcare — November 11, 2025 at 9:20 AM ET
- Stephens Investment — November 18, 2025 at 8:00 AM CT
- Jefferies Global Healthcare — November 20, 2025 at 12:30 PM GMT
A live webcast will be available via the company's Investor Relations Calendar at https://investors.bio-techne.com/ir-calendar.